Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Recover your password.
A password will be e-mailed to you.
LOS ANGELES, March 02, 2023 (GLOBE NEWSWIRE) — ViaDerma, Inc. (OTC Pink: VDRM) is pleased to provide an update on current business activities.
President & CEO, Dr. Chris Otiko said, “We are off to a great start in this new year after enduring some delays because of pandemic related supply chain issues and our strict internal quality control measures. We are happy to be back on track and very excited for what the future holds.”
“Our current marketing efforts are geared towards targeting institutions, hospitals, and doctor’s offices domestically and internationally for product sales, along with licensing the use of Vitastem and Vitastem Ultra. So far, we have received overwhelmingly positive feedback from those who have tested our products and expect this to result in larger volume sales in 2023.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: https://viaderma.com
Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: info@viadermalicensing.com
Phone: 310-734-6111
Follow ViaDerma on Twitter: https://twitter.com/viaderma
Follow ViaDerma on Facebook: https://www.facebook.com/ViaDermaLicensing/
Get real time updates directly on you device, subscribe now.